906745-11-7 Usage
Uses
Used in Pharmaceutical Industry:
Tert-butyl (5-hydroxypyridin-3-yl)carbamate is used as a protecting group for amino acids to prevent unwanted chemical reactions during the synthesis of peptide molecules and prodrugs. Its stability under standard conditions and solubility in organic solvents such as ethanol and dimethyl sulfoxide make it a valuable component in the development of pharmaceutical compounds.
In the synthesis of peptide molecules:
Tert-butyl (5-hydroxypyridin-3-yl)carbamate is used to protect the amine group of amino acids, allowing for the controlled formation of peptide bonds and preventing side reactions that could compromise the integrity of the final product.
In the development of prodrugs:
This protecting group is utilized in the synthesis of prodrugs, which are biologically inactive compounds that are converted into active drugs within the body. By protecting the amine group of amino acids, tert-butyl (5-hydroxypyridin-3-yl)carbamate enables the creation of prodrugs with improved pharmacokinetic properties, such as enhanced solubility, stability, and bioavailability.
Check Digit Verification of cas no
The CAS Registry Mumber 906745-11-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,6,7,4 and 5 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 906745-11:
(8*9)+(7*0)+(6*6)+(5*7)+(4*4)+(3*5)+(2*1)+(1*1)=177
177 % 10 = 7
So 906745-11-7 is a valid CAS Registry Number.
906745-11-7Relevant academic research and scientific papers
PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE
-
Page/Page column 36, (2008/06/13)
[Problem] To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain. [Means for Solution] We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.
